At a glance
A family of peptides involved in reproductive hormone signaling.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source explores hormone responses and reproductive research. Verify the exact fragment and population before comparing results across papers.[2][1][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Kisspeptin.
A comprehensive adverse-effect profile is not established by the source record. Consult the cited studies for what was measured and what remains uncertain.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 3 units (0.03 mL) |
| Weeks 3–8 (or 3–12) | 200 mcg | 6 units (0.06 mL) |
Frequency: Inject once daily subcutaneously. This schedule follows a conservative titration to assess individual response[2][1]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support physiological reproductive hormone signaling through upstream GnRH stimulation[1].
- Schedule: Daily subcutaneous injections for 8–12 weeks.
- Dose Range: 100–200 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for precise low-volume measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 100 mcg daily for 1–2 weeks to assess sensitivity[2].
- Titrate: Increase to 200 mcg daily if tolerated and necessary[1].
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; avoid prolonged continuous use to prevent tachyphylaxis[1].
- Timing: Any consistent time; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions with desiccant if possible[4].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable up to ~4 weeks[16]; avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (45° for thin individuals, 90° with adequate fat)[6].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
- Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, upper arms, upper buttocks) to avoid tissue irritation[3].
- Use a new sterile syringe for each injection; dispose of used syringes in a proper sharps container[8].
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Kisspeptin, 10 mg each):
- 8 weeks ≈ 1 vial
- 12 weeks ≈ 2 vials
- 16 weeks ≈ 3 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 16 weeks (3 vials): 9 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 04
Source document
Prospec Bio — Lyophilized peptide storage recommendations (opens in a new tab)www.prospecbio.com
Back to overview ↑ - 05
Source document
Empower Pharmacy — Bacteriostatic Water handling and 28-day discard guidelines (opens in a new tab)www.empowerpharmacy.com
Back to overview ↑ - 07
Public health resource
CDC Vaccine Administration Guidelines — Subcutaneous route: no aspiration required (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
NCBI Bookshelf — Parenteral medication administration: sterile technique and disposal (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
COMMUNITY · EXTERNAL FORUM
Discuss Kisspeptin with the community
Explore member conversations and ask questions on glp1chat. Forum posts and listings are not vetted or endorsed by Pep Science, and they are not medical advice or editorial evidence.
Visit the community (opens in a new tab)Continue exploring
Related topics are not interchangeable compounds or formulations.